PolarityTS (PTE) Reports Q4 Loss of $4.29

PolarityTS (NASDAQ: PTE) reported Q4 EPS of ($4.29), $3.38 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $800 thousand.

Denver Lough, MD, PhD, Chairman & CEO said, "I'm very excited by the progress we made in 2018. We successfully transitioned from a limited market release of our SkinTE product to the beginning of a regional market release. With this transition we have begun to hire a sales force to drive revenue and effectively commercialize SkinTE as we move through 2019. I'm proud of what we have accomplished, but I'm also proud to be part of a team that is focused on delivering the type of technology that can disrupt the current standard of care."

"As we look to 2019, there are a number of milestones that I look forward to, including: the continued commercial rollout of SkinTE in the US; maturation of data that we expect will help drive continued adoption of SkinTE and validation of our platform; an inflection of medical conference presentations by doctors with SkinTE experience to provide further evidence of its efficacy; more clinical data and case studies that show the benefits of SkinTE over the current standard of care, skin grafts; and the market introduction of OsteoTE in the US."

For earnings history and earnings-related data on PolarityTS (PTE) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Rothschild Redburn Upgrades Apple (AAPL) to Buy
• Genco rejects Diana Shipping takeover bid as undervalued